相关实验视频
Updated: Jun 9, 2025

08:15
Gastrointestinal Motility Monitor GIMM
Published on: December 1, 2010
30.8K
卢比普罗可以通过由EP3前列腺受体刺激的TRPC4激活来改善远端段特异性的结肠收缩
Byeongseok Jeong1,2, Jun Hyung Lee3, Jin-A Lee1
1Department of Physiology, Chosun University College of Medicine, Gwangju 61452, Republic of Korea.
Pharmaceuticals (Basel, Switzerland)
|October 26, 2024
概括
卢比 (LUB) 激活了远端结肠中的EP3受体和TRPC4通道,增强了胃肠运动性. 这一细分特定的行动支持个性化的便秘管理和排便反射.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 促性药物增强胃肠道 (GI) 收缩性,治疗便秘.
- 路比普 (LUB) 激活了CLC-2化通道,增加了胃肠道液体,促进了便的运动.
- 卢布的药理作用的确切机制尚不清楚.
研究的目的:
- 调查卢比普 (LUB) 是否激活了正规的短暂受体潜在阴离子通道4型 (TRPC4).
- 为了确定EP3受体刺激是否介导LUB对TRPC4.的作用.
- 探索LUB对结肠收缩性的细分特异性影响.
主要方法:
- 在小鼠结肠条上进行同位素张力记录,以评估LUB诱导的收缩性.
- 定量实时聚合酶连锁反应 (qRT-PCR) 用于量化EP受体亚型mRNA表达.
- 评估TRPC4阻断剂和EP3抗剂对LUB刺激的收缩的影响.
主要成果:
- 与近端细分相比,LUB诱导了远端结肠的显著收缩.
- 远端结肠中高EP3受体mRNA表达与增强的收缩相关.
- TRPC4阻断剂和EP3抗剂减少了LUB诱导的收缩,这表明EP3介导的TRPC4激活.
结论:
- 路比普 (LUB) 通过间接激活远端结肠中的TRPC4通道来增强结肠质量运动.
- 卢布的细分市场特异性影响支持对便秘管理的个性化方法.
- 这些发现阐明了LUB的机制,有可能改善排便反射障碍的治疗方法.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
139
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
139
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
212
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
212
Drugs for Treatment of Diarrhea-Predominant IBS
149
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
149
Drugs Affecting GI Tract Motility: Other Laxatives
172
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
172
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
186
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
186
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
261
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
261

